Subscription banner for an ophthalmic newsletter
Laboratoires Théa Acquires Sepofarsen and Ultevursen from ProQR Therapeutics

ProQR Therapeutics and Laboratoires Théa have reached an agreement through which ProQR will transfer...

read more
Laboratoires Théa Acquires Sepofarsen and Ultevursen from ProQR Therapeutics
August 08, 2023
Glaukos' iDose TR for Glaucoma Hits the Market

Glaukos Corporation's iDose TR, using Celanese's VitalDose EVA (Ethylene Vinyl Acetate), to provide ...

read more
Glaukos' iDose TR for Glaucoma Hits the Market
March 04, 2024
Roche’s Vabysmo Receives CHMP Recommendation for RVO Indication

Roche announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medic...

read more
Roche’s Vabysmo Receives CHMP Recommendation for RVO Indication
July 02, 2024
Alcon Completes Acquisition of BELKIN Vision

Alcon has finalized its acquisition of BELKIN Vision, marking a significant expansion of its glaucom...

read more
Alcon Completes Acquisition of BELKIN Vision
July 02, 2024
VSY Biotechnology GmbH Achieved Strong Growth in Q1 2023

VSY Biotechnology GmbH is moving towards achieving its growth targets with incremental steps....

read more
VSY Biotechnology GmbH Achieved Strong Growth in Q1 2023
May 16, 2023
Amring Pharmaceuticals Rebrands as Nordic Pharma

In a significant corporate rebranding, Amring Pharmaceuticals has officially adopted the name Nordic...

read more
Amring Pharmaceuticals Rebrands as Nordic Pharma
March 05, 2024
CMS J-Code for Glaukos’ iDose TR Becomes Active

Glaukos Corporation has confirmed the activation of the CMS Healthcare Common Procedure Coding Syste...

read more
CMS J-Code for Glaukos’ iDose TR Becomes Active
July 03, 2024
FDA Approves Clobetasol Propionate Eye Drop for Post-Op Inflammation and Pain

The U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension...

read more
FDA Approves Clobetasol Propionate Eye Drop for Post-Op Inflammation and Pain
March 05, 2024
NurExone Launches Study on Exopten Therapy for Glaucoma Treatment

NurExone Biologic has initiated a preclinical study to investigate the potential of its exosome-base...

read more
NurExone Launches Study on Exopten Therapy for Glaucoma Treatment
July 03, 2024
The Optical Company Acquires Adelaide Eye Care Practices in Australia

In a landmark move that expands its network to 60 locations, The Optical Company (TOC) has officiall...

read more
The Optical Company Acquires Adelaide Eye Care Practices in Australia
March 05, 2024
More